Results 31 to 40 of about 554,574 (392)

MHC-II neoantigens shape tumor immunity and response to immunotherapy

open access: yesNature, 2019
The ability of the immune system to eliminate and shape the immunogenicity of tumours defines the process of cancer immunoediting1. Immunotherapies such as those that target immune checkpoint molecules can be used to augment immune-mediated elimination ...
Elise Alspach   +23 more
semanticscholar   +1 more source

EXPRESSION OF A FUNCTIONAL CHIMERIC lg-MHC CLASS II PROTEIN [PDF]

open access: yes, 1992
composed of the a- and ß-chains of the MHC class I1 I-E molecule fused to antibody V regions derived from anti-human CD4 mAb MT310. Expression vectors were constructed containing the functional, rearranged gene segments coding for the V region domains of
Becker, Andrea   +8 more
core   +1 more source

Forecast of cytotoxic T lymphocyte epitope using sequence weighting and artificial neural network based on EasyPred modeler [PDF]

open access: yesExploration of Immunology
Aim: Cytotoxic T lymphocytes (CTL) examine the major histocompatibility complex (MHC) class I ligands on nucleated cells to detect antigens derived from pathogens and cancer cells.
Satarudra Prakash Singh   +2 more
doaj   +1 more source

Cryptic MHC Polymorphism Revealed but Not Explained by Selection on the Class IIB Peptide-Binding Region [PDF]

open access: yes, 2012
The immune genes of the major histocompatibility complex (MHC) are characterized by extraordinarily high levels of nucleotide and haplotype diversity. This variation is maintained by pathogen-mediated balancing selection that is operating on the peptide ...
Barcaccia   +32 more
core   +1 more source

Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours

open access: yesOpen Biology, 2022
MHC-I and MHC-II molecules are critical components of antigen presentation and T cell immunity to pathogens and cancer. The two monoclonal transmissible devil facial tumours (DFT1, DFT2) exploit MHC-I pathways to overcome immunological anti-tumour and ...
Chrissie E. B. Ong   +5 more
doaj   +1 more source

A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes [PDF]

open access: yes, 1989
Peptides that are antigenic for T lymphocytes are ligands for two receptors, the class I or II glycoproteins that are encoded by genes in the major histocompatibility complex, and the idiotypic / chain T-cell antigen receptor1–9. That a peptide must bind
A Sette   +30 more
core   +1 more source

Expression of MHC Class I and II in Growing Ovarian Follicles of Young and Old Laying Hens, Gallus domesticus

open access: yesThe Journal of Poultry Science, 2005
The aim of this study was to determine whether the expressions of MHC class I and II in the ovarian follicles change with follicular growth and aging of birds. Theca layer of white follicles (WF), the largest and the third largest preovulatory follicles
Kalpana Subedi, Yukinori Yoshimura
doaj   +1 more source

Induction of specific tolerance by intrathymic injection of recipient muscle cells transfected with donor class I major histocompatibility complex. [PDF]

open access: yes, 1994
Induction of tolerance to allogeneic MHC antigens has been a goal in the field of transplantation because it would reduce or eliminate the need for generalized immunosuppression.
Geissler, Edward K.   +5 more
core   +1 more source

High functional allelic diversity and copy number in both MHC classes in the common buzzard

open access: yesBMC Ecology and Evolution, 2023
Background The major histocompatibility complex (MHC), which encodes molecules that recognize various pathogens and parasites and initiates the adaptive immune response in vertebrates, is renowned for its exceptional polymorphism and is a model of ...
Jamie Winternitz   +4 more
doaj   +1 more source

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

open access: yesScience Translational Medicine, 2018
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
S. Rodig   +17 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy